APA (7th ed.) Citation

Azad, A. A., Gurney, H., Underhill, C., Horvath, L., Voskoboynik, M., Li, X., . . . Perabo, F. (2025). Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC. Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, 43(2), 435-445. https://doi.org/10.1007/s10637-025-01533-8

Chicago Style (17th ed.) Citation

Azad, Arun A., et al. "Phase 1 Study of HP518, a PROTAC AR Degrader in Patients with MCRPC." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies 43, no. 2 (2025): 435-445. https://doi.org/10.1007/s10637-025-01533-8.

MLA (9th ed.) Citation

Azad, Arun A., et al. "Phase 1 Study of HP518, a PROTAC AR Degrader in Patients with MCRPC." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, vol. 43, no. 2, 2025, pp. 435-445, https://doi.org/10.1007/s10637-025-01533-8.